Regeneron Expects Mid-Teens R&D Expense Growth Rate in 2027

John Kim

1 min read

Add as a preferred source on Google

Regeneron Expects Mid-Teens R&D Expense Growth Rate in 2027

The company also expects to recognize Sanofi’s $1 billion upfront payment in Q4.

By John Kim

Published Oct 30, 2026, 4:24 PM EDT

A glass vial and pipette rest on a laboratory bench / TokenPost.ai

Regeneron Pharmaceuticals expects research and development expenses to rise at a mid-teens rate in 2027 compared with 2026, setting out a higher spending outlook on its third-quarter 2026 earnings call.

The company also expects to recognize Sanofi’s $1 billion upfront payment in Q4.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.